ImmunityBio

CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

Retrieved on: 
Thursday, February 24, 2022
Biotechnology, General Health, Pharmaceutical, Health, CytRx, Therapy, Niemann–Pick disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Head, European Medicines Agency, NASDAQ, ImmunityBio, NPC, Marketing, Gaucher's disease, Company, Glioblastoma, Pancreatic cancer, Review, Orientation, Food, News, Neurodegeneration, Committee for Medicinal Products for Human Use, OTCQB, Cancer, EMA, MAA, Patient, Union, Technology, Committee, CHMP, Research, Marketing Authorisation Application, Pharmaceutical industry

CytRx licensed arimoclomol to Orphazyme in exchange for milestone payments and royalties.

Key Points: 
  • CytRx licensed arimoclomol to Orphazyme in exchange for milestone payments and royalties.
  • The trend vote indicates that the CHMP's current orientation is to not approve arimoclomol when it convenes by the end of March 2022.
  • In addition, CytRxs drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties.
  • Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease.

Athenex Announces Appointment of Chief Financial Officer

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, ImmunityBio, Risk, NHA, CFA, NASDAQ, CFO, COVID-19, Company, Drug development, PricewaterhouseCoopers, Investor relations, Sale, Safety, BS, Director, University of Virginia, Leadership, Roth Capital Partners, Cancer, MBA, Patient, University, Cell, Carnegie Mellon University, History, GFW, SEC, Pharmaceutical industry, Financial services, Management, KUUR

BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that Mr. Joe Annoni will join Athenex as its new Chief Financial Officer and Officer of the Company, effective immediately.

Key Points: 
  • BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that Mr. Joe Annoni will join Athenex as its new Chief Financial Officer and Officer of the Company, effective immediately.
  • The Board of Directors joins me in welcoming Joe to his new position as CFO, said Johnson Lau, Chief Executive Officer ofAthenex.
  • Joes appointment will provide Athenex with the seasoned leadership in finance to help us execute on our corporate objectives.
  • Mr. Annoni, Chief Financial Officer, said, I am honored to join Athenexs leadership team at such a pivotal time and to lead its finance organization as we refocus the companys efforts to unlock shareholder value.

Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility

Retrieved on: 
Tuesday, February 15, 2022
NASDAQ, History, Patient, Cancer, ImmunityBio, Risk, SEC, U.S. Securities and Exchange Commission, Security (finance), Cell, Safety, Sale, Â, COVID-19, Investor relations, GLOBE, Drug development, Pharmaceutical industry, KUUR

We are pleased with the opportunity to partner with ImmunityBio on the sale of our leasehold at the Dunkirk facility, said Jeffrey Yordon, Chief Operating Officer, President Athenex Pharmaceutical Division, They are well positioned to build on the foundation that we established in this state-of-the-art facility, and we look forward to continuing to work with the Dunkirk team in the future as a contract manufacturing partner.

Key Points: 
  • We are pleased with the opportunity to partner with ImmunityBio on the sale of our leasehold at the Dunkirk facility, said Jeffrey Yordon, Chief Operating Officer, President Athenex Pharmaceutical Division, They are well positioned to build on the foundation that we established in this state-of-the-art facility, and we look forward to continuing to work with the Dunkirk team in the future as a contract manufacturing partner.
  • A portion of the proceeds from the deal announced on January 12, 2022 will be used to service the Companys debt obligations, and for other general corporate purposes.
  • Further information about the agreement and use of proceeds of the sale can be found in a Form 8-K filed by Athenex with the Securities and Exchange Commission on February 15, 2022.
  • Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements.

ImmunityBio Completes Acquisition of Athenex’s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility

Retrieved on: 
Tuesday, February 15, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Oncology, NASDAQ, HIV, Food, CEO, SEC, COVID-19 vaccine, Forward-looking statement, Review, RNA transfection, Private Securities Litigation Reform Act, Infection, III, Clinical trial, GMP, ISO, Regulation of tobacco by the U.S. Food and Drug Administration, Lung cancer, NMIBC, Interleukin, U.S. Securities and Exchange Commission, FDA, Cancer, BCG, Acquisition, CIS, Severe acute respiratory syndrome coronavirus 2, COVID-19, Pharmaceutical industry, Vaccine, ImmunityBio

The new state-of-the-art biotech production facility, located in Dunkirk, New York (Chautauqua County), includes clean rooms for upstream and downstream manufacturing activities, as well as fill and finish and large-scale lyophilization capabilities.

Key Points: 
  • The new state-of-the-art biotech production facility, located in Dunkirk, New York (Chautauqua County), includes clean rooms for upstream and downstream manufacturing activities, as well as fill and finish and large-scale lyophilization capabilities.
  • The full-scale facility enables ImmunityBio to substantially expand and diversify its existing manufacturing capacity in the U.S. and through its strategic collaborators in Africa.
  • We are thrilled to add the Dunkirk manufacturing facility and the talented team running it to our organization, said Richard Adcock, President and CEO of ImmunityBio.
  • This facility provides production capacity at a significant scale here in the U.S. and at significantly lower capital cost than building a facility like this from the ground up.

ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer

Retrieved on: 
Monday, February 14, 2022
Oncology, Health, Communications, FDA, Infectious Diseases, General Health, Public Relations, Investor Relations, HIV, Death, Infection, Adult, Clinical trial, Pancreatic cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cohort study, Maintenance, Patrick Soon-Shiong, BCG, CIS, American Cancer Society, Bladder cancer, Natural killer T cell, Carcinoma, Journal, Recurrence, RNA transfection, III, Cystectomy, Immunogenic cell death, NMIBC, Interleukin, Woman, NASDAQ, Mortality, Incidence, COVID-19 vaccine, Immune system, GMP, Treatment of lung cancer, Cancer, Disease, Severe acute respiratory syndrome coronavirus 2, Valrubicin, Vanderbilt-Ingram Cancer Center, ASCO, Memory, Patient, Quality of life, Food, Cell death, Man, Medicine, American Journal of Clinical Oncology, Immunotherapy, Immunity, Cohort, Cancer Breakthroughs 2020, FDA, NK, Pharmaceutical industry, Vaccine, Medical imaging, ImmunityBio, the Study and Breakthrough Designation, ImmunityBio, THE STUDY AND BREAKTHROUGH DESIGNATION, IMMUNITYBIO

The data showed sustained complete response rates in patients with BCG-unresponsive non-muscle invasive carcinoma in situ (NMIBC CIS) bladder cancer (Cohort A) and with papillary disease (Cohort B).

Key Points: 
  • The data showed sustained complete response rates in patients with BCG-unresponsive non-muscle invasive carcinoma in situ (NMIBC CIS) bladder cancer (Cohort A) and with papillary disease (Cohort B).
  • In the papillary disease arm of the study (Cohort B), 57% of patients are disease free at 12 months and 53% at 18 months.
  • This study suggests that BCG induces trained immunity as the prime, while N-803 serves as a vital boost for innate immune memory.
  • The latest data from this trial exceeds AUA-FDA workshop benchmarks for both the magnitude of complete remission and the duration of complete response for new therapies for BCG-unresponsive bladder cancer.

CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

Retrieved on: 
Monday, February 14, 2022
Oncology, Health, FDA, Research, Science, Pharmaceutical, Biotechnology, NASDAQ, Patient, Food, Cancer, ImmunityBio, European Medicines Agency, Company, Neurodegeneration, OTCQB, Endpoint security, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Niemann–Pick disease, Gaucher's disease, NPC, EU, CytRx, Committee, European Directive on Traditional Herbal Medicinal Products, FDA, NDA, Research, Type, Committee for Medicinal Products for Human Use, Pharmaceutical industry

CytRx licensed arimoclomol to Orphazyme in exchange for milestone payments and royalties.

Key Points: 
  • CytRx licensed arimoclomol to Orphazyme in exchange for milestone payments and royalties.
  • Orphazyme plans to request the Type C Meeting in Q2 2022.
  • CytRx will continue to share publicly available updates as they relate to the Company's licensing deal with Orphazyme.
  • Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease.

Athenex to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Wednesday, February 9, 2022
NASDAQ, GLOBE, Cell, Conference, Board, ImmunityBio, Cancer, Sale, Risk, Investor relations, Patient, Safety, SEC, CEO, History, Drug development, Webcast, COVID-19, Pharmaceutical industry, KUUR

BUFFALO, N.Y., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board Chairman, and Daniel Lang, President, Athenex Cell Therapy, will present at the 11th Annual SVB Leerink Global healthcare Conference on Thursday, February 17, 2022, at 3:00 P.M.

Key Points: 
  • BUFFALO, N.Y., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board Chairman, and Daniel Lang, President, Athenex Cell Therapy, will present at the 11th Annual SVB Leerink Global healthcare Conference on Thursday, February 17, 2022, at 3:00 P.M.
  • A live audio webcast of the presentation and replay will be available in the Events & Presentations section of the Athenex website at https://ir.athenex.com/investor-calendar .
  • An audio archive of the webcast will also be available on Athenexs website for the following 90 days.
  • Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements.

Bluejay Therapeutics Announces the Appointment of Nancy Shulman, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, February 2, 2022
Therapy, CMC, University, Chicago (franchise), Immunoglobulin G, Amgen, AbbVie, Â, Adenosine, GLOBE, Hotel des Indes (The Hague), Division, NDA, Stanford University, Internal medicine, Five-prime cap, Moses Austin, Hepatitis C, CEO, Apple tree, Roche, Pediatrics, Chemistry, Cancer and Leukemia Group B, Immunology, Hepatitis B, Drug development, Technology transfer, Leukemia & Lymphoma Society, HBsAg, Leadership, Infection, Chiron Corporation, Hepatocyte, Gilead Sciences, Leukemia, SQZ, GMP, NNRTI, Hoffman, HCV, Industry, CHBV, Faculty, Patient, A2A, SAN, Bayer, Partner, HIV, Disease, Catalant, HBV, NIH, Pharmaceutical industry, Management, ImmunityBio, Searle, Blue jay, Biochemistry, Genentech

SAN MATEO, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private biopharmaceutical company focused on the development of innovative cures for infectious diseases, today announced that Nancy Shulman, M.D., joined Bluejay as chief medical officer, bringing over 20 years of clinical development experience with her to Bluejay Therapeutics.

Key Points: 
  • SAN MATEO, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private biopharmaceutical company focused on the development of innovative cures for infectious diseases, today announced that Nancy Shulman, M.D., joined Bluejay as chief medical officer, bringing over 20 years of clinical development experience with her to Bluejay Therapeutics.
  • Prior to Bluejay, Dr. Shulman worked at Roche, Genentech, AbbVie, and most recently at Ambys Medicines, where she was the vice president of translational medicine.
  • Prior to joining industry, Nancy was an NIH-funded clinical/translational HIV researcher at Stanford University and was on the faculty in the Division of Infectious Diseases.
  • Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.

ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival

Retrieved on: 
Tuesday, January 18, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hoag (health network), Treatment of lung cancer, Mortality, Private Securities Litigation Reform Act, SEC, Ix, NASDAQ, Chan, Infection, PFS, Cancer, NMIBC, Cohort study, Vii, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, Mergers and acquisitions, Safety, COVID-19 vaccine, Disease, CIS, Pancreatic cancer, Interleukin, Food, Medicine, FDA, Maintenance, U.S. Securities and Exchange Commission, College, Survival, Forward-looking statement, Patient, Society, Radiation, Progression-free survival, Time, HIV, Therapy, OS, RNA transfection, ORR, III, RECIST, Survival rate, DCR, Dor, Severe acute respiratory syndrome coronavirus 2, GMP, BCG, Pharmaceutical industry, Vaccine, ImmunityBio

Surgery and subsequent adjuvant chemotherapy are the preferred treatment options for pancreatic cancer today, but the five-year survival rate for late-stage cases is just 3% .

Key Points: 
  • Surgery and subsequent adjuvant chemotherapy are the preferred treatment options for pancreatic cancer today, but the five-year survival rate for late-stage cases is just 3% .
  • The median overall survival in this highly advanced group of patients, who failed two to six prior lines of treatment, is 5.8 months (95% CI: 3.9, 6.9 months) exceeding the approximately three-month historical median overall survival.
  • Median overall survival in this group was 6.3 months (95% CI: 5.0, 9.8 months), more than doubling the historical overall survival.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

CytRx to Hold Town Hall for Stockholders on Thursday, January 20th

Retrieved on: 
Tuesday, January 18, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Neurodegeneration, Research, Patient, CytRx, OTCQB, ImmunityBio, Baozou Big News Events, Gaucher's disease, News, Niemann–Pick disease, NPC, Therapy, Cancer, Pharmaceutical industry

CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it will hold a town hall for stockholders on Thursday, January 20, 2022 at 4:30 PM Eastern.

Key Points: 
  • CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it will hold a town hall for stockholders on Thursday, January 20, 2022 at 4:30 PM Eastern.
  • The town hall will be led by the Companys Chief Executive Officer, Dr. Stephen Snowdy, and include a question-and-answer session.
  • The town hall can be accessed here .
  • A recording of the town hall will be available on CytRx's website under the News & Events section following the event.